CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Menezes, Soraya M ^a   Decanine, Daniele ^b   Brassat, David ^c   Khouri, Ricardo ^a,b   Schnitman, Saul V ^b   Kruschewsky, Ramon ^d   López, Giovanni ^e   Alvarez, Carolina ^a,e   Talledo, Michael ^e   Gotuzzo, Eduardo ^e,f   Vandamme, Anne Mieke ^a,g   Galvão Castro, Bernardo ^b,d   Liblau, Roland ^c   Weyenbergh, Johan V ^a,b,h  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c CHU PURPAN   (France)

^d ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^e INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^f UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^g INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^h Institute for Investigation in Immunology INCT   (Brazil)

Author keywords

B cell; CD86; Costimulatory CD80; Disease severity; Ex vivo; Gender; HTLV 1; Human; Interferon alpha beta; Multiple sclerosis; Neuroinflammatory disease

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; BETA INTERFERON; BIOLOGICAL MARKER; CD86 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG TARGETING; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; SEX DIFFERENCE; T LYMPHOCYTE; TROPICAL SPASTIC PARAPARESIS; UPREGULATION;

ADULT; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HTLV-I INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PARAPARESIS, TROPICAL SPASTIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84896740503     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-18     Document Type: Article

References (132)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77:7415-7419. 10.1073/pnas.77.12.7415, 350514, 6261256.
2. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995, 69:2863-2868. 188982, 7707509.
3. de The G, Bomford R. An HTLV-I vaccine: why, how, for whom?. AIDS Res Hum Retroviruses 1993, 9:381-386. 10.1089/aid.1993.9.381, 8318266.
4. Hlela C, Shepperd S, Khumalo NP, Taylor GP. The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown. AIDS Rev 2009, 11:205-214.
5. Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007, 7:266-281. 10.1016/S1473-3099(07)70081-6, 17376384.
6. Bangham CR. The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J Gen Virol 2003, 84:3177-3189. 10.1099/vir.0.19334-0, 14645900.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452. 10.1212/WNL.33.11.1444, 6685237.
8. Osame M, Igata A, Matsumoto M, et al. HTLV-I-associated myelopathy (HAM): treatment trials, retrospective survey, and clinical and laboratory findings. Hematol Rev 1990, 3:271-284.
9. Umehara F, Izumo S, Nakagawa M, Ronquillo AT, Takahashi K, Matsumuro K, Sato E, Osame M. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1993, 52:424-430. 10.1097/00005072-199307000-00010, 8355031.
10. Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 1996, 2:345-355. 10.3109/13550289609146899, 8912211.
11. Oh U, Jacobson S. Treatment of HTLV-I-as+sociated myelopathy/tropical spastic paraparesis: toward rational targeted therapy. Neurol Clin 2008, 26:781-797. ix-x, 10.1016/j.ncl.2008.03.008, 2610848, 18657726.
12. Lezin A, Gillet N, Olindo S, Signate A, Grandvaux N, Verlaeten O, Belrose G, de Carvalho BM, Hiscott J, Asquith B, et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 2007, 110:3722-3728. 10.1182/blood-2007-04-085076, 17717136.
13. Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H, Babiker A, Rudge P, Usuku K, et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology 2006, 3:63. 10.1186/1742-4690-3-63, 1590049, 16984654.
14. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L, Taylor G, Mokhber N, Mahmoudi M, Abbaszadegan MR, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol 2012, 250:87-93. 10.1016/j.jneuroim.2012.05.004, 22727800.
15. Oh U, Yamano Y, Mora CA, Ohayon J, Bagnato F, Butman JA, Dambrosia J, Leist TP, McFarland H, Jacobson S. Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol 2005, 57:526-534. 10.1002/ana.20429, 15786444.
16. Furukawa Y, Fujisawa J, Osame M, Toita M, Sonoda S, Kubota R, Ijichi S, Yoshida M. Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP). Blood 1992, 80:1012-1016.
17. Tendler CL, Greenberg SJ, Burton JD, Danielpour D, Kim SJ, Blattner WA, Manns A, Waldmann TA. Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis. J Cell Biochem 1991, 46:302-311. 10.1002/jcb.240460405, 1757474.
18. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, Osame M. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998, 4:586-593. 10.3109/13550289809114225, 10065900.
19. Kuroda Y, Matsui M. Cerebrospinal fluid interferon-gamma is increased in HTLV-I-associated myelopathy. J Neuroimmunol 1993, 42:223-226. 10.1016/0165-5728(93)90014-P, 8429106.
20. Nakamura S, Nagano I, Yoshioka M, Shimazaki S, Onodera J, Kogure K. Detection of tumor necrosis factor-alpha-positive cells in cerebrospinal fluid of patients with HTLV-I-associated myelopathy. J Neuroimmunol 1993, 42:127-130. 10.1016/0165-5728(93)90001-F, 8429097.
21. Nishimoto N, Yoshizaki K, Eiraku N, Machigashira K, Tagoh H, Ogata A, Kuritani T, Osame M, Kishimoto T. Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurol Sci 1990, 97:183-193. 10.1016/0022-510X(90)90217-B, 2401896.
22. Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 2008, 14:429-436. 10.1038/nm1745, 18376405.
23. Koyanagi Y, Itoyama Y, Nakamura N, Takamatsu K, Kira J, Iwamasa T, Goto I, Yamamoto N. In vivo infection of human T-cell leukemia virus type I in non-T cells. Virology 1993, 196:25-33. 10.1006/viro.1993.1451, 8356797.
24. Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol 1999, 77:304-311. 10.1046/j.1440-1711.1999.00835.x, 10457196.
25. Pardigon N, Cambouris C, Bercovici N, Lemaitre F, Liblau R, Kourilsky P. Delayed and separate costimulation in vitro supports the evidence of a transient " excited" state of CD8+ T cells during activation. J Immunol 2000, 164:4493-4499.
26. Lal RB, Rudolph DL, Dezzutti CS, Linsley PS, Prince HE. Costimulatory effects of T cell proliferation during infection with human T lymphotropic virus types I and II are mediated through CD80 and CD86 ligands. J Immunol 1996, 157:1288-1296.
27. Takamoto T, Makino M, Azuma M, Kanzaki T, Baba M, Sonoda S. HTLV-I-infected T cells activate autologous CD4+ T cells susceptible to HTLV-I infection in a costimulatory molecule-dependent fashion. Eur J Immunol 1997, 27:1427-1432. 10.1002/eji.1830270620, 9209495.
28. Chang TT, Jabs C, Sobel RA, Kuchroo VK, Sharpe AH. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med 1999, 190:733-740. 10.1084/jem.190.5.733, 2195617, 10477557.
29. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995, 96:2195-2203. 10.1172/JCI118274, 185869, 7593605.
30. Miller SD, Vanderlugt CL, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, Bluestone JA. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995, 3:739-745. 10.1016/1074-7613(95)90063-2, 8777719.
31. Zeinstra E, Wilczak N, De Keyser J. Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7-1 and B7-2. J Neuroimmunol 2003, 135:166-171. 10.1016/S0165-5728(02)00462-9, 12576238.
32. Bauvois B, Nguyen J, Tang R, Billard C, Kolb JP. Types I and II interferons upregulate the costimulatory CD80 molecule in monocytes via interferon regulatory factor-1. Biochem Pharmacol 2009, 78:514-522. 10.1016/j.bcp.2009.05.005, 19433065.
33. Genc K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997, 99:2664-2671. 10.1172/JCI119455, 508112, 9169496.
34. Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Mult Scler 2008, 14:166-176.
35. Espejo C, Brieva L, Ruggiero G, Rio J, Montalban X, Martinez-Caceres EM. IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis. Mult Scler 2004, 10:630-635. 10.1191/1352458504ms1094oa, 15584487.
36. Rudick RA, Goelz SE. Beta-interferon for multiple sclerosis. Exp Cell Res 2011, 317:1301-1311. 10.1016/j.yexcr.2011.03.002, 21396360.
37. nterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:655-661.
38. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995, 45:1277-1285.
39. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996, 46:1016-1021. 10.1212/WNL.46.4.1016, 8780082.
40. Shibayama K, Nakamura T, Nagasato K, Shirabe S, Tsujihata M, Nagataki S. Interferon-alpha treatment in HTLV-I-associated myelopathy Studies of clinical and immunological aspects. J Neurol Sci 1991, 106:186-192. 10.1016/0022-510X(91)90256-7, 1802967.
41. Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP 1990, New York: Raven Press.
42. Grassi MF, Olavarria VN. Kruschewsky Rde A, Mascarenhas RE, Dourado I, Correia LC, De Castro-Costa CM, Galvao-Castro B: Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011, 83:1269-1274. 10.1002/jmv.22087, 21567429.
43. Adaui V, Verdonck K, Best I, Gonzalez E, Tipismana M, Arevalo J, Vanham G, Campos M, Zimic M, Gotuzzo E. SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness. J Neurovirol 2006, 12:456-465. 10.1080/13550280601039634, 17162661.
44. Olindo S, Lezin A, Cabre P, Merle H, Saint-Vil M, Edimonana Kaptue M, Signate A, Cesaire R, Smadja D. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci 2005, 237:53-59. 10.1016/j.jns.2005.05.010, 15972218.
45. Gotuzzo E, Cabrera J, Deza L, Verdonck K, Vandamme AM, Cairampoma R, Vizcarra D, Cabada M, Narvarte G, De las Casas C. Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1-associated tropical spastic paraparesis. Clin Infect Dis 2004, 39:939-944. 10.1086/423957, 15472843.
46. Lima MA, Bica RB, Araujo AQ. Gender influence on the progression of HTLV-I associated myelopathy/tropical spastic paraparesis. J Neurol Neurosurg Psychiatry 2005, 76:294-296.
47. Norris PJ, Hirschkorn DF, DeVita DA, Lee TH, Murphy EL. Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells. Virulence 2010, 1:19-28. 10.4161/viru.1.1.9868, 2903746,2903746, 20640055.
48. Furukawa Y, Bangham CR, Taylor GP, Weber JN, Osame M. Frequent reversible membrane damage in peripheral blood B cells in human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Clin Exp Immunol 2000, 120:307-316. 10.1046/j.1365-2249.2000.01211.x, 1905651, 10792381.
49. Liu Z, Pelfrey CM, Cotleur A, Lee JC, Rudick RA. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001, 112:153-162. 10.1016/S0165-5728(00)00403-3, 11108944.
50. Ramgolam VS, Sha Y, Marcus KL, Choudhary N, Troiani L, Chopra M, Markovic-Plese S. B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J Immunol 2011, 186:4518-4526. 10.4049/jimmunol.1000271, 21368231.
51. Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, Arimura K, Matsuoka M, Ohara Y. In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 2009, 6:19. 10.1186/1742-4690-6-19, 2653460, 19228429.
52. Yamano Y, Araya N, Sato T, Utsunomiya A, Azakami K, Hasegawa D, Izumi T, Fujita H, Aratani S, Yagishita N, et al. Abnormally high levels of virus-infected IFN-gamma + CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One 2009, 4:e6517. 10.1371/journal.pone.0006517, 2715877, 19654865.
53. O'Neill SK, Cao Y, Hamel KM, Doodes PD, Hutas G, Finnegan A. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol 2007, 179:5109-5116.
54. Morbach H, Wiegering V, Richl P, Schwarz T, Suffa N, Eichhorn EM, Eyrich M, Girschick HJ. Activated memory B cells may function as antigen-presenting cells in the joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2011, 63:3458-3466. 10.1002/art.30569, 21792842.
55. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80:707-718. 10.1016/0092-8674(95)90349-6, 7534215.
56. Brown JA, Greenwald RJ, Scott S, Schweitzer AN, Satoskar AR, Chung C, Schopf LR, van der Woude D, Sypek JP, Sharpe AH. T helper differentiation in resistant and susceptible B7-deficient mice infected with Leishmania major. Eur J Immunol 2002, 32:1764-1772. 10.1002/1521-4141(200206)32:6<1764::AID-IMMU1764>3.0.CO;2-V, 12115660.
57. Mbow ML, DeKrey GK, Titus RG. Leishmania major induces differential expression of costimulatory molecules on mouse epidermal cells. Eur J Immunol 2001, 31:1400-1409. 10.1002/1521-4141(200105)31:5<1400::AID-IMMU1400>3.0.CO;2-J, 11466703.
58. Furukawa Y, Mandelbrot DA, Libby P, Sharpe AH, Mitchell RN. Association of B7-1 co-stimulation with the development of graft arterial disease: studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Am J Pathol 2000, 157:473-484. 10.1016/S0002-9440(10)64559-2, 1850132, 10934151.
59. Newton S, Ding Y, Chung CS, Chen Y, Lomas-Neira JL, Ayala A. Sepsis-induced changes in macrophage co-stimulatory molecule expression: CD86 as a regulator of anti-inflammatory IL-10 response. Surg Infect (Larchmt) 2004, 5:375-383. 10.1089/sur.2004.5.375, 2253680, 15744129.
60. Nolan A, Kobayashi H, Naveed B, Kelly A, Hoshino Y, Hoshino S, Karulf MR, Rom WN, Weiden MD, Gold JA. Differential role for CD80 and CD86 in the regulation of the innate immune response in murine polymicrobial sepsis. PLoS One 2009, 4:e6600. 10.1371/journal.pone.0006600, 2719911, 19672303.
61. Nolan A, Weiden M, Kelly A, Hoshino Y, Hoshino S, Mehta N, Gold JA. CD40 and CD80/86 act synergistically to regulate inflammation and mortality in polymicrobial sepsis. Am J Respir Crit Care Med 2008, 177:301-308. 10.1164/rccm.200703-515OC, 2218847, 17989345.
62. Sellebjerg F, Jensen J, Ryder LP. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J Neuroimmunol 1998, 84:179-187. 10.1016/S0165-5728(97)00261-0, 9628461.
63. Svenningsson A, Dotevall L, Stemme S, Andersen O. Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. J Neuroimmunol 1997, 75:59-68. 10.1016/S0165-5728(96)00234-2, 9143238.
64. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, Hafler DA. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995, 182:1985-1996. 10.1084/jem.182.6.1985, 2192240, 7500044.
65. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. 10.1038/nature10251, 3182531, 21833088.
66. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704. 10.1146/annurev.immunol.26.021607.090331, 18173375.
67. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2:116-126. 10.1038/nri727, 11910893.
68. Montanheiro PA, de Oliveira ACP, Smid J, Fukumori LM, Olah I, da S Duarte AJ, Casseb J. The elevated interferon gamma production is an important immunological marker in HAM/TSP pathogenesis. Scand J Immunol 2009, 70:403-407. 10.1111/j.1365-3083.2009.02291.x, 19751276.
69. Luna T, Santos SB, Nascimento M, Porto MA, Muniz AL, Carvalho EM, Jesus AR. Effect of TNF-alpha production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Braz J Med Biol Res 2011, 44:1134-1140. 10.1590/S0100-879X2011007500140, 3255079, 22011961.
70. Moens B, Decanine D, Menezes SM, Khouri R, Silva-Santos G, Lopez G, Alvarez C, Talledo M, Gotuzzo E, de Almeida KR, et al. Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-alpha in HTLV-1-associated myelopathy. PLoS Negl Trop Dis 2012, 6:e1729. 10.1371/journal.pntd.0001729, 3404116, 22848768.
71. Moldovan IR, Rudick RA, Cotleur AC, Born SE, Lee JC, Karafa MT, Pelfrey CM. Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J Neuroimmunol 2003, 141:132-140. 10.1016/S0165-5728(03)00221-2, 12965264.
72. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
73. Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, Trotter JL, Karr RW. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest 1995, 95:2783-2789. 10.1172/JCI117982, 295963, 7539461.
74. Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, Yao S, Tsushima F, Narazaki H, Anand S, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010, 116:1291-1298. 10.1182/blood-2010-01-265975, 2938239, 20472828.
75. Hirata S, Senju S, Matsuyoshi H, Fukuma D, Uemura Y, Nishimura Y. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol 2005, 174:1888-1897.
76. Zhao J, Freeman GJ, Gray GS, Nadler LM, Glimcher LH. A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB. J Exp Med 1996, 183:777-789. 10.1084/jem.183.3.777, 2192348, 8642282.
77. Paun A, Pitha PM. The IRF family, revisited. Biochimie 2007, 89:744-753. 10.1016/j.biochi.2007.01.014, 2139905, 17399883.
78. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, Relman DA. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 2010, 5:e9753. 10.1371/journal.pone.0009753, 2842296, 20339534.
79. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866. 10.1038/sj.onc.1203239, 10602461.
80. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635. 10.1126/science.1071924, 12040173.
81. Li J, Colovai AI, Cortesini R, Suciu-Foca N. Cloning and functional characterization of the 5′-regulatory region of the human CD86 gene. Hum Immunol 2000, 61:486-498. 10.1016/S0198-8859(00)00099-9, 10773351.
82. Panitch HS. Systemic alpha-interferon in multiple sclerosis: long-term patient follow-up. Arch Neurol 1987, 44:61-63. 10.1001/archneur.1987.00520130047016, 3800723.
83. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 2006, 103:720-725. 10.1073/pnas.0507631103, 1334651, 16407133.
84. Azran I, Schavinsky-Khrapunsky Y, Aboud M. Role of tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 2004, 1:20. 10.1186/1742-4690-1-20, 514576, 15310405.
85. Szymocha R, Akaoka H, Brisson C, Beurton-Marduel P, Chalon A, Bernard A, Didier-Bazes M, Belin MF, Giraudon P. Astrocytic alterations induced by HTLV type 1-infected T lymphocytes: a role for tax-1 and tumor necrosis factor alpha. AIDS Res Hum Retroviruses 2000, 16:1723-1729. 10.1089/08892220050193218, 11080817.
86. Szymocha R, Akaoka H, Dutuit M, Malcus C, Didier-Bazes M, Belin MF, Giraudon P. Human T-cell lymphotropic virus type 1-infected T lymphocytes impair catabolism and uptake of glutamate by astrocytes via tax-1 and tumor necrosis factor alpha. J Virol 2000, 74:6433-6441. 10.1128/JVI.74.14.6433-6441.2000, 112151, 10864655.
87. Brown DA, Nelson FB, Reinherz EL, Diamond DJ. The human interferon-gamma gene contains an inducible promoter that can be transactivated by tax I and II. Eur J Immunol 1991, 21:1879-1885. 10.1002/eji.1830210815, 1831129.
88. Podojil JR, Kohm AP, Miller SD. CD4+ T cell expressed CD80 regulates central nervous system effector function and survival during experimental autoimmune encephalomyelitis. J Immunol 2006, 177:2948-2958.
89. Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin Exp Immunol 2004, 138:499-506. 10.1111/j.1365-2249.2004.02624.x, 1809242, 15544628.
90. Santos SB, Porto AF, Muniz AL, de Jesus AR, Magalhaes E, Melo A, Dutra WO, Gollob KJ, Carvalho EM. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC Infect Dis 2004, 4:article 7.
91. Colisson R, Barblu L, Gras C, Raynaud F, Hadj-Slimane R, Pique C, Hermine O, Lepelletier Y, Herbeuval JP. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood 2010, 115:2177-2185. 10.1182/blood-2009-06-224741, 20007807.
92. Tattermusch S, Skinner JA, Chaussabel D, Banchereau J, Berry MP, McNab FW, O'Garra A, Taylor GP, Bangham CR. Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 2012, 8:e1002480. 10.1371/journal.ppat.1002480, 3266939, 22291590.
93. Feng J, Misu T, Fujihara K, Saito H, Takahashi T, Kohnosu T, Shiga Y, Takeda A, Sato S, Takase S, Itoyama Y. Interferon-alpha significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP. J Neuroimmunol 2003, 141:170-173. 10.1016/S0165-5728(03)00219-4, 12965269.
94. Macchi B, Faraoni I, Mastino A, D'Onofrio C, Romeo G, Bonmassar E. Protective effect of interferon beta on human T cell leukaemia virus type I infection of CD4+ T cells isolated from human cord blood. Cancer Immunol Immunother 1993, 37:97-104. 10.1007/BF01517041, 8100486.
95. D'Onofrio C, Perno CF, Mazzetti P, Graziani G, Calio R, Bonmassar E. Depression of early phase of HTLV-I infection in vitro mediated by human beta-interferon. Br J Cancer 1988, 57:481-488. 10.1038/bjc.1988.111, 2246394, 2899440.
96. Arnason BG. Long-term experience with interferon beta-1b (Betaferon) in multiple sclerosis. J Neurol 2005, 252(3):iii28-iii33.
97. Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther 2008, 8:1435-1447. 10.1517/14712598.8.9.1435, 18694361.
98. McKeage K. Interferon-beta-1b: in newly emerging multiple sclerosis. CNS Drugs 2008, 22:787-792. 10.2165/00023210-200822090-00005, 18698876.
99. Mirowska D, Skierski J, Paz A, Koronkiewicz M, Zaborski J, Kruszewska J, Czlonkowski A, Czlonkowska A. Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-beta-1a treatment in multiple sclerosis patients. J Neurol 2003, 250:1229-1236. 10.1007/s00415-003-0170-9, 14586608.
100. Revel M, Chebath J, Mangelus M, Harroch S, Moviglia GA. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult Scler 1995, 1(1):S5-S11.
101. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993, 46:145-153. 10.1016/0165-5728(93)90244-S, 8360326.
102. Van Weyenbergh J, Lipinski P, Abadie A, Chabas D, Blank U, Liblau R, Wietzerbin J. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients. J Immunol 1998, 161:1568-1574.
103. Zhao T, Yasunaga J, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka M. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood 2009, 113:2755-2764. 10.1182/blood-2008-06-161729, 19064727.
104. Barbeau B, Mesnard JM. Making sense out of antisense transcription in human T-cell lymphotropic viruses (HTLVs). Viruses 2011, 3:456-468. 10.3390/v3050456, 3185765, 21994742.
105. Karp CL, van Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?. Curr Opin Neurol 2001, 14:361-368. 10.1097/00019052-200106000-00016, 11371761.
106. Wang X, Chen M, Wandinger KP, Williams G, Dhib-Jalbut S. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 2000, 165:548-557.
107. Marijanovic Z, Ragimbeau J, van der Heyden J, Uze G, Pellegrini S. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J 2007, 407:141-151. 10.1042/BJ20070605, 2267396, 17627610.
108. Roisman LC, Jaitin DA, Baker DP, Schreiber G. Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. J Mol Biol 2005, 353:271-281. 10.1016/j.jmb.2005.08.042, 16171819.
109. Domanski P, Nadeau OW, Platanias LC, Fish E, Kellum M, Pitha P, Colamonici OR. Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta. J Biol Chem 1998, 273:3144-3147. 10.1074/jbc.273.6.3144, 9452423.
110. de Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff SJ, Zaker-Tabrizi L, Fung KY, Forster SC, Beddoe T, et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat Immunol 2013, 14:901-907. 10.1038/ni.2667, 23872679.
111. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264. 10.1146/annurev.biochem.67.1.227, 9759489.
112. Muller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Silvennoinen O, Harpur AG, Barbieri G, Witthuhn BA, Schindler C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 1993, 366:129-135. 10.1038/366129a0, 8232552.
113. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992, 70:313-322. 10.1016/0092-8674(92)90105-L, 1386289.
114. Pellegrini S, John J, Shearer M, Kerr IM, Stark GR. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol 1989, 9:4605-4612. 363606, 2513475.
115. Couturier N, Bucciarelli F, Nurtdinov RN, Debouverie M, Lebrun-Frenay C, Defer G, Moreau T, Confavreux C, Vukusic S, Cournu-Rebeix I, et al. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 2011, 134:693-703. 10.1093/brain/awr010, 21354972.
116. Grumbach IM, Fish EN, Uddin S, Majchrzak B, Colamonici OR, Figulla HR, Heim A, Platanias LC. Activation of the Jak-Stat pathway in cells that exhibit selective sensitivity to the antiviral effects of IFN-beta compared with IFN-alpha. J Interferon Cytokine Res 1999, 19:797-801. 10.1089/107999099313659, 10454351.
117. da Silva AJ, Brickelmaier M, Majeau GR, Lukashin AV, Peyman J, Whitty A, Hochman PS. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res 2002, 22:173-188. 10.1089/107999002753536149, 11911800.
118. Sancéau J, Hiscott J, Delattre O, Wietzerbin J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 2000, 19:3372-3383. 10.1038/sj.onc.1203670, 10918594.
119. Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol 2006, 176:4343-4351.
120. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010, 467:214-217. 10.1038/nature09337, 3051279, 20829794.
121. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008, 118:1680-1690. 10.1172/JCI33342, 2276397, 18382764.
122. Teige I, Treschow A, Teige A, Mattsson R, Navikas V, Leanderson T, Holmdahl R, Issazadeh-Navikas S. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol 2003, 170:4776-4784.
123. Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, Marrack P. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c B-cell population is important for the development of autoimmunity. Blood 2011, 118:1305-1315. 10.1182/blood-2011-01-331462, 3152497, 21543762.
124. Calderón-Gómez E, Lampropoulou V, Shen P, Neves P, Roch T, Stervbo U, Rutz S, Kuhl AA, Heppner FL, Loddenkemper C, et al. Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis. Eur J Immunol 2011, 41:1696-1708. 10.1002/eji.201041041, 3431508, 21469107.
125. Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P. Cohen Tervaert JW, Hupperts R, Damoiseaux J: Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. J Neuroimmunol 2011, 239:80-86. 10.1016/j.jneuroim.2011.08.019, 21940055.
126. Brito-Melo GE, Souza JG, Barbosa-Stancioli EF, Carneiro-Proietti AB, Catalan-Soares B, Ribas JG, Thorum GW, Rocha RD, Martins-Filho OA. Establishing phenotypic features associated with morbidity in human T-cell lymphotropic virus type 1 infection. Clin Diagn Lab Immunol 2004, 11:1105-1110. 524787, 15539514.
127. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006, 180:63-70. 10.1016/j.jneuroim.2006.06.029, 1769354, 16904756.
128. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005, 62:258-264. 10.1001/archneur.62.2.258, 15710854.
129. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688. 10.1056/NEJMoa0706383, 18272891.
130. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787. 10.1016/S0140-6736(11)61649-8, 22047971.
131. Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, Abdulghani AA, Goldfarb M, Chieffo N, Totoritis MC. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004, 111:28-37. 10.1016/j.clim.2004.01.006, 15093549.
132. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005, 23:4390-4398. 10.1200/JCO.2005.09.018, 15994148.